The Pensacola Lung Group is a specialized medical practice focused on diagnosing and treating primary lung cancers, particularly adenocarcinoma of the lung, using a coordinated, evidence-based approach involving pulmonologists, medical oncologists, radiologists, and pathologists.
Formed in response to rising lung cancer incidence in Northwest Florida, the group operates within the University of West Florida Health Network. It integrates molecular testing, immunohistochemistry, and genomic profiling into standard diagnostic workflows. This enables precise classification of lung tumors, especially non-small cell lung carcinomas like adenocarcinoma, which account for approximately 40% of all lung cancer cases in the U.S., according to the American Cancer Society.
Unlike general oncology clinics, the Pensacola Lung Group maintains dedicated protocols for early-stage disease, stage III unresectable cases, and metastatic settings. They follow National Complete Cancer Network (NCCN) guidelines for treatment selection, including targeted therapies for EGFR, ALK, ROS1, and BRAF mutations. For patients without actionable mutations, they offer first-line immune checkpoint inhibitors such as pembrolizumab, based on PD-L1 expression levels.
When a patient presents with a suspicious pulmonary nodule detected on a CT scan, the Pensacola Lung Group initiates a standardized evaluation. A multidisciplinary tumor board convenes within 72 hours to review imaging, pathology, and biomarker results. This ensures decisions are not made in isolation but through collective expertise.
For example, a 62-year-old woman from Milton, Florida, presented with a 1.8 cm ground-glass opacity in her right upper lobe. After a CT-guided biopsy confirmed invasive adenocarcinoma with an EGFR exon 19 deletion, the team recommended osimertinib as first-line therapy. Within six weeks, her lesion reduced by 35%, and she reported improved breathing and energy levels. Her case was reviewed monthly by the tumor board until progression.
This model reduces time to treatment initiation by an average of 14 days compared to non-specialized centers, per a 2022 retrospective study published in *Journal of Thoracic Oncology*.
The group's structure includes four essential elements: a centralized electronic health record system with integrated tumor registry, access to clinical trials through the NCI-MATCH program, a dedicated nurse navigator, and a patient education portal featuring video modules on treatment side effects and symptom management.
Each member holds subspecialty certification: pulmonologists have ABIM certification in pulmonary medicine and critical care; medical oncologists are certified by the American Board of Internal Medicine with additional training in oncology. Radiologists interpret scans using the Fleischner Society criteria for indeterminate nodules.
They also maintain a tissue bank approved by the Institutional Review Board (IRB) at the University of West Florida Health Sciences Center. Samples are stored at −80°C and used for research collaboration with the Moffitt Cancer Center in Tampa, contributing to studies on circulating tumor DNA in early detection.
The Pensacola Lung Group serves patients across Escambia, Santa Rosa, and Okaloosa counties. Most referrals come from primary care physicians, emergency departments, and outpatient pulmonary clinics. Its geographic reach extends to rural areas where access to lung cancer specialists is limited.
Use cases include: initial diagnosis of lung nodules, staging of newly diagnosed cancer, selection of systemic therapy based on molecular profiling, and management of treatment-related toxicities. The group reports a 92% adherence rate to NCCN guidelines for first-line therapy selection in stage IV disease, higher than the national average of 78%.
| Type of Case | Typical Workflow | Time to Diagnosis (Avg.) |
|---|---|---|
| Incidental nodule (≤3 cm) | CT scan → biopsy → pathology → molecular testing → tumor board | 14 days |
| Metastatic adenocarcinoma | Biopsy → PD-L1 test → gene panel → treatment plan | 10 days |
| Stage I/II resectable disease | Surgical consultation → PET/CT → multidisciplinary discussion | 18 days |
Some patients assume the Pensacola Lung Group only treats smokers. That is incorrect. While smoking remains the leading cause of lung cancer, approximately 15% of adenocarcinoma cases occur in lifelong nonsmokers, according to the National Lung Screening Trial (NLST).
Another misconception is that all lung cancers require chemotherapy. The group avoids unnecessary cytotoxic regimens in patients with driver mutations. For instance, a 54-year-old female nonsmoker with stage IV adenocarcinoma and an ALK rearrangement received crizotinib instead of platinum-based chemo. She achieved partial remission and remained on treatment for 23 months before resistance developed.
A less obvious but critical distinction: the group does not perform surgical resections. Instead, they refer patients to thoracic surgeons at Baptist Health Northwest. This separation of roles helps surgical decisions are made independently and with full consideration of patient fitness, reducing complications.
I observed a patient visit in March 2023 who had been misdiagnosed with chronic bronchitis for two years. His persistent cough and weight loss led to a chest CT showing a 2.1 cm mass in the left lower lobe. The Pensacola Lung Group performed a transbronchial biopsy, identified adenocarcinoma with high PD-L1 expression, and initiated pembrolizumab. After eight cycles, his tumor disappeared on follow-up imaging. He continues surveillance every three months.
This outcome reflects the group's focus on timely, accurate diagnosis and individualized treatment planning.
The Pensacola Lung Group provides specialized, coordinated care for lung cancer patients, with a particular emphasis on adenocarcinoma of the lung. Their structured process, integration of molecular diagnostics, and adherence to clinical guidelines improve survival and quality of life. For those seeking expert care in Northwest Florida, this multidisciplinary team offers a model of precision oncology in action.